Health

Results: 2581-2592 of 8201

Tracer Biotechnologies Announces Strategic Partnership with QIAGEN to Advance Blood-Based MRD Testing for Solid Tumors

PR Newswire associated0

As Pilgrims Arrive in Makkah, Saudi Arabia Rolls Out Massive Operation to Safeguard Health

Biocytogen Secures Japan Patent for RenMab Platform, Expands Global Patent Portfolio for RenMice Fully Human Antibody/TCR Platform

Measles outbreaks continue with risk of holidays causing surge

New partnership brings more dynamic strength and mobility-focused classes to iFIT’s platform.

iFIT Adds More Ways to Workout, Brings Club Pilates and YogaSix Content to Its Platform

CORE-VNS Study Further Validates Effectiveness of LivaNova’s VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy

PR Newswire associated0

FutureCeuticals, Inc. Announces Peer-Reviewed Publication Highlighting Cellular Health and Immune Support Benefits of vitAlign®

LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy

Polpharma Group Supports Urgent EU Action to Safeguard Access to Medicines and Strengthen European Pharmaceutical Sovereignty

Sarah Harkcom, General Counsel at Scientist.com, Wins European Legal Innovation & Technology “Innovation Trailblazer” Award

TeleTracking and Palantir Partner to Transform Healthcare Operations with AI-Powered Insights

Figure 1. DAZALS exploratory overall survival analysis at one-year – patients who received 300 mg of dazucorilant compared to patients who received only placebo.

Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting